Abstract: This invention provides compositions and methods for enhancing delivery of glucocorticoids and ascomycins such as hydrocortisone, cyclosporin and FK506 across into and across one or more layers of the skin for the treatment of psoriasis and other inflammatory diseases of the skin.
Type:
Grant
Filed:
August 24, 2000
Date of Patent:
May 4, 2004
Assignee:
CellGate, Inc.
Inventors:
Jonathan B. Rothbard, Paul A. Wender, P. Leo McGrane, Lalitha V. S. Sista, Thorsten A. Kirschberg
Abstract: The present invention relates to a method for lowering the serum phosphate level of a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer or repeat unit. The amino nitrogen atom of the diallylamine repeat unit can be substituted by one or two substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the diallylamine repeat unit comprises an ammonium or quaternary ammonium group, the monomer will further comprise a suitable anion, such as a conjugate base of a pharmaceutically acceptable acid.
Type:
Grant
Filed:
November 5, 1997
Date of Patent:
April 27, 2004
Assignee:
Genzyme Corporation
Inventors:
W. Harry Mandeville, III, Stephen Randall Holmes-Farley
Abstract: The invention relates to a sprayable or vaporizable cosmetic composition, in particular in the form of an aerosol, comprising, in a cosmetically acceptable aqueous or aqueous/alcoholic medium, at least one fixing and/or conditioning polymer and at least one alkyl acrylate/alkyl methacrylate/acrylic acid copolymer.
Abstract: Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release of the drug has occurred.
Type:
Grant
Filed:
October 25, 2001
Date of Patent:
April 20, 2004
Assignee:
DepoMed, Inc.
Inventors:
Gloria Gusler, Bret Berner, Mei Chau, Aimee Padua
Abstract: The invention provides wet skin treatment compositions for use during bathing. The compositions are activated by water and retained efficiently on skin. The compositions impart desirable benefits to skin, are perceived to absorb quickly on wet skin, and leave the skin feeling clean, but non-greasy.
Type:
Grant
Filed:
April 29, 2003
Date of Patent:
April 6, 2004
Assignee:
Unilever Home & Personal Care USA, division of Conopco,
Inc.
Inventors:
Michael Paul Aronson, Liang Sheng Tsaur
Abstract: The present invention relates to a sustained release composition comprising micron particles of labile agent and a method of preparing and using the sustained release composition. The invention further relates to micron particles of a labile agent and a method of preparing the micron particles.
The method of the invention for preparing a composition for the sustained release of a labile agent, comprises forming a suspension comprising the labile agent dispersed in a polymer solution comprising at least one biocompatible polymer and at least one polymer solvent. The suspension is then wet milled to achieve micron particles of the labile agent. The polymer solvent is then removed resulting in a solid polymer/labile agent matrix. The composition for sustained release of a labile agent is likewise prepared according to the method of the invention.
Type:
Grant
Filed:
July 18, 2002
Date of Patent:
March 30, 2004
Assignee:
Alkermes Controlled Therapeutics, Inc.
Inventors:
Mark A. Tracy, Kevin L. Ward, Warren E. Jaworowicz
Abstract: A wasp controlling liquid formulation, which comprises a pesticidal compound as an active ingredient and at least 30% by weight of a saturated hydrocarbon that has a boiling point from 90° C. to 200° C., provides superior potency and an ability to knock down or kill wasps before the wasp has a chance to formidably sting someone.
Abstract: Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invention include wound healing agents, antibiotics, anti-inflammatories, anti-oxidants, anti-proliferatives, immunosupressants, anti-infective and anti-cancer agents.
Type:
Grant
Filed:
September 6, 2000
Date of Patent:
March 16, 2004
Assignee:
Conjuchem, Inc.
Inventors:
Alan M. Ezrin, Angelica Fleser, Martin Robitaille, Peter G. Milner, Dominique P. Bridon
Abstract: Biocompatible compositions comprising polyanionic polysaccharides combined with hydrophobic bioabsorbable polymers as well as methods for making and using the compositions are described.
Type:
Grant
Filed:
September 4, 2001
Date of Patent:
March 9, 2004
Assignee:
Genzyme Corporation
Inventors:
James W. Burns, Keith E. Greenawalt, Louis Masi
Abstract: The use of one or more cosurfactant (surfactant B) in a mixture with one or more surfactants different from surfactant B (surfactant A) for reducing the binding of surfactant A to the surface of the skin.
Abstract: The invention provides a hydrogen-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogen-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.
Abstract: A sustained-release preparation comprising a bioactive substance having an acidic group and a biodegradable polymer having an optionally protected basic group which improves the rate of incorporation of the bioactive substance, suppresses its leakage early after adminstration, and exhibits constantly suppressed release for an extended period of time.
Type:
Grant
Filed:
May 31, 2001
Date of Patent:
February 24, 2004
Assignee:
Takeda Chemical Industries, Ltd.
Inventors:
Yoshio Hata, Hikaru Taira, Jun Sato, Satoshi Iinuma
Abstract: The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.
Abstract: The present invention relates to a method for reducing adhesions associated with post-operative surgery. The present method comprises administering or affixing a polymeric composition preferably comprising chain extended, coupled or crosslinked polyester/poly(oxyalkylene) ABA triblocks or AB diblocks having favorable EO/LA ratios to a site in the body which has been subjected to trauma, e.g. by surgery, excision or inflammatory disease. In the present invention, the polymeric material provides a barrier to prevent or reduce the extent of adhesions forming.
Abstract: Improved drug compositions and methods useful in the treatment of male erectile dysfunction. An optimized mixture of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil in a buffer containing L-arginine and glycine is to be injected into the penile tissue to produce an erection in otherwise impotent men.
Abstract: Compositions comprising glycerides containing conjugated linoleic acid moieties. These glycerides are prepared by an enzymatic conversion process which is selective to provide specific isomers, advantageously the cis9, trans11 and trans10, cis12 linoleic acid isomers or vice versa. The compositions may be blended with complementary fats and may be used in foods, food supplements and pharmaceutical compositions.
Type:
Grant
Filed:
February 9, 2000
Date of Patent:
February 17, 2004
Assignee:
Loders Croklaan B.V.
Inventors:
Frederick William Cain, Stephen Raymond Moore, Gerald Patrick McNeill, Olga Cornelia Zwemmer
Abstract: Novel emulsion compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel emulsion compositions of the present invention include drug-containing emulsions adsorbed onto solid particles which may be further formulated into solid dosage forms, methods of preparing such emulsion compositions and their uses thereof. The emulsion compositions and their dosage forms improve the drug-load and the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.
Type:
Grant
Filed:
February 23, 2001
Date of Patent:
February 17, 2004
Assignee:
CIMA Labs Inc.
Inventors:
S. Indiran Pather, Sangeeta V. Gupte, Rajendra K. Khankari, John Hontz, Ramya Kumbale
Abstract: The present invention relates to a controlled release drug delivery system comprising a drug which is susceptible to enzymatic degradation by enzymes present in the intestinal tract; and a polymeric matrix which undergoes erosion in the gastrointestinal tract comprising a hydrogel-forming polymer selected from the group consisting of (a) polymers which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by intestinal enzymes; and (b) polymers which are not themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inhibiting degradation of said drug by intestinal enzymes; wherein when the matrix comprises a polymer belonging to group (b) the delivery system further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes and when the matrix comprises a polymer belon
Type:
Grant
Filed:
February 28, 1997
Date of Patent:
February 17, 2004
Assignee:
Yissum Research Development Company of The Hebrew University
of Jerusalem
Inventors:
Abraham Rubinstein, Raphael Radai, Michael Friedman, Boaz Tirosh, Muhammad Baluom, Taher Nassar
Abstract: A lipid or other hydrophobic or amphiphilic compound (collectively referred to herein as “hydrophobic compounds”) is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as compared to release from the polymeric matrix not incorporating the hydrophobic compound into the polymeric material. In contrast to methods in which a surfactant or lipid is added as an excipient, the hydrophobic compound is actually integrated into the polymeric matrix, thereby modifying the diffusion of water into the microparticle and diffusion of solubilized drug out of the matrix. The integrated hydrophobic compound also prolongs degradation of hydrolytically unstable polymers forming the matrix, further delaying release of encapsulated drug.
Type:
Grant
Filed:
March 5, 2003
Date of Patent:
February 10, 2004
Assignee:
Acusphere, Inc.
Inventors:
Howard Bernstein, Donald Chickering, Sarwat Khattak, Julie Straub
Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.